GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines-Reference-Cited by-同舟云学术

GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines

Published:2024-05-23 Issue:6 Volume:1 Page:
ISSN:2836-9386
Container-title:NEJM AI
language:en
Short-container-title:NEJM AI

Author:

Ferber Dyke¹²^ORCID,Wiest Isabella C.³⁴^ORCID,Wölflein Georg³⁵^ORCID,Ebert Matthias P.⁴⁶⁷^ORCID,Beutel Gernot⁸^ORCID,Eckardt Jan-Niklas³⁹^ORCID,Truhn Daniel¹⁰^ORCID,Springfeld Christoph¹²^ORCID,Jäger Dirk¹²^ORCID,Kather Jakob Nikolas¹²³⁹^ORCID

Affiliation:

1. National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany

2. Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany

3. Else Kröner Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany

4. Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

5. School of Computer Science, University of St. Andrews, St. Andrews, United Kingdom

6. DKFZ-Hector Cancer Institute at the University Medical Center, Mannheim, Germany

7. Molecular Medicine Partnership Unit, EMBL, Heidelberg, Germany

8. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Medizinische Hochschule Hannover, Hannover, Germany

9. Department of Medicine I, University Hospital Dresden, Dresden, Germany

10. Department of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, Aachen, Germany

Publisher

Massachusetts Medical Society

Reference36 articles.

1. Cancer Research Institute. FDA approval timeline of active immunotherapies. 2022 (https://www.cancerresearch.org/regulatory-approval-timeline-of-active-immunotherapies).

2. U.S. Food and Drug Administration. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. plus-bevacizumab-unresectable-hepatocellular. June 1 2020 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma).

3. U.S. Food and Drug Administration. FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. March 11 2020 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma).

4. U.S. Food and Drug Administration. FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma. October 24 2022 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma).

5. U.S. Food and Drug Administration. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. April 20 2020 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Capabilities of Generative AI Tools in Understanding Medical Papers: Qualitative Study;JMIR Medical Informatics;2024-09-04

2. Large language models could make natural language again the universal interface of healthcare;Nature Medicine;2024-08-23

3. Accuracy and consistency of publicly available Large Language Models as clinical decision support tools for the management of colon cancer;Journal of Surgical Oncology;2024-08-19

4. Vignette-based comparative analysis of ChatGPT and specialist treatment decisions for rheumatic patients: results of the Rheum2Guide study;Rheumatology International;2024-08-10

5. Customizing GPT-4 for clinical information retrieval from standard operating procedures;2024-06-24